Maziar Mike Doustdar faced a daunting task when he took the reins as CEO of Novo Nordisk in August. The pharma didn’t hold onto its early lead in obesity, and needed big swings to right the ship. While the company lost its bid to steal away Metsera, Doustdar has promised to be assertive in resetting the Danish drug giant. He'll talk with executive editor Drew Armstrong about what comes next

While much of the biotech world has faced fluctuating fortunes in 2025, dealmaking has continued at a strong pace through the year. M&A in particular has been strong, ending 2025 with several $10 billion-plus acquisitions. Industry leaders join John Carroll to discuss how these trends will likely to play out in the year ahead.

Stay tuned -- more to come.

LB Pharmaceuticals went public in September 2025 in the first big biotech listing in the US since the previous February. CEO Heather Turner will give a behind-the-scenes look at the why and how. 

Over the past year we’ve seen several top R&D groups shift strategy in oncology. What’s driving these changes and what’s ahead in 2026 that will continue to shape the industry’s investment in experimental cancer therapies and diagnostics? Top execs will review the oncology landscape that lies ahead.

GSK has a new CEO taking over on January 1. But its science is staying the course and Chief Scientific Officer Tony Wood is staying put. Hear how he navigates organizational change and what comes next for the pharma’s pipeline. 

Join experts from Slalom and Salesforce to hear how AI and data-driven strategies can address business needs, drive innovation and productivity, and deliver a patient-focused experience. They'll explore how hyper-personalization can help healthcare & life science companies accelerate their work.

Staff turnover, delays and general confusion have been a hallmark of the Trump Administration’s FDA — even as it promises to streamline the process for rare disease drugs. Companies in the crosshairs join Endpoints to share how they’re navigating the shifting environment.

Stay tuned -- more to come.

In the face of tariff threats, large biopharmas spent the past year announcing new US-based manufacturing hubs. Global supply chains are realigning. How are companies handling the uncertainty?

Eric Tokat, Co-President of Investment Banking at Centerview Partners, joins us to share his perspective on deals done in 2025 and the outlook for 2026.